You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

MOTRIN IB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Motrin Ib, and when can generic versions of Motrin Ib launch?

Motrin Ib is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in MOTRIN IB is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-five suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Motrin Ib

A generic version of MOTRIN IB was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MOTRIN IB?
  • What are the global sales for MOTRIN IB?
  • What is Average Wholesale Price for MOTRIN IB?
Summary for MOTRIN IB
Drug patent expirations by year for MOTRIN IB
Recent Clinical Trials for MOTRIN IB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MiamiPhase 2
Guangzhou Kangqi Medical Technology Co., LTDPhase 1
Weill Medical College of Cornell UniversityPhase 4

See all MOTRIN IB clinical trials

Pharmacology for MOTRIN IB

US Patents and Regulatory Information for MOTRIN IB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc MOTRIN IB ibuprofen TABLET;ORAL 019012-003 Dec 17, 1990 OTC Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for MOTRIN IB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.